Robert Harrington to Biomarkers
This is a "connection" page, showing publications Robert Harrington has written about Biomarkers.
Connection Strength
0.605
-
Targeting Inflammation in Coronary Artery Disease. N Engl J Med. 2017 09 21; 377(12):1197-1198.
Score: 0.096
-
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016 Dec 13; 134(24):1918-1930.
Score: 0.091
-
Biomarker-Based Prediction of Recurrent?Ischemic Events in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2022 11 01; 80(18):1735-1747.
Score: 0.034
-
Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. Eur Heart J Acute Cardiovasc Care. 2022 Jun 07; 11(4):336-349.
Score: 0.033
-
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 11 05; 140(19):1578-1589.
Score: 0.028
-
Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2018 05 14; 11(9):856-864.
Score: 0.025
-
Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. Int J Cardiol. 2017 Oct 15; 245:271-276.
Score: 0.024
-
Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. Int J Cardiol. 2017 Apr 01; 232:264-270.
Score: 0.023
-
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017 Feb; 63(2):573-584.
Score: 0.023
-
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016 06 21; 5(6).
Score: 0.022
-
Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circ Cardiovasc Interv. 2015 Jun; 8(6):e002314.
Score: 0.021
-
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014 Jan 21; 129(3):293-303.
Score: 0.018
-
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. J Am Coll Cardiol. 2013 Jul 16; 62(3):242-251.
Score: 0.018
-
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA?CER) trial. Eur Heart J. 2013 Jun; 34(23):1723-31.
Score: 0.018
-
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013 Sep; 99(17):1282-7.
Score: 0.018
-
Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. Am Heart J. 2012 Nov; 164(5):689-697.e3.
Score: 0.017
-
Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012 Sep; 5(9):927-35.
Score: 0.017
-
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011 Aug 05; 109(4):428-36.
Score: 0.016
-
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010 Nov; 104(5):976-83.
Score: 0.015
-
Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant. 2010 Jul; 25(7):2368-75.
Score: 0.014
-
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). Am J Cardiol. 2009 Nov 15; 104(10):1330-5.
Score: 0.014
-
Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol. 2006 Jan 17; 47(2):312-8.
Score: 0.011
-
Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med. 2005 May; 12(5):431-8.
Score: 0.010